Related references
Note: Only part of the references are listed.Glucocorticoid-induced osteoporosis: 2019 concise clinical review
G. Adami et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up
Anne M. Horne et al.
CALCIFIED TISSUE INTERNATIONAL (2019)
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper
Quentin A. Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Osteoblast autophagy in glucocorticoid-induced osteoporosis
Lufei Wang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Inhaled glucocorticoids are associated with vertebral fractures in COPD patients
Pedro Assed Goncalves et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2018)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARγ2 signaling in GIO rats
Ya-jun Yang et al.
ACTA PHARMACOLOGICA SINICA (2018)
WNT16 overexpression partly protects against glucocorticoid-induced bone loss
Claes Ohlsson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2018)
Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease
Olorunfemi A. Oshagbemi et al.
BONE (2018)
Autophagy as a target for glucocorticoid-induced osteoporosis therapy
Gengyang Shen et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Glucocorticoids inhibit notch target gene expression in osteoblasts
Stefano Zanotti et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway
M. Hoff et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Therapeutic Mechanisms of Glucocorticoids
Jolien Vandewalle et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
Glucocorticoids suppress Wnt16 expression in osteoblasts in vitro and in vivo
Susanne Hildebrandt et al.
SCIENTIFIC REPORTS (2018)
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
Kenneth G. Saag et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Glucocorticoid-induced osteoporosis: an update
Juliet Compston
ENDOCRINE (2018)
Osteoanabolic Agents for Osteoporosis
Andrea V. Haas et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2018)
Association Between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone
Kristian F. Axelsson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Case-aced Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ
Aliya A. Khan et al.
JOURNAL OF CLINICAL DENSITOMETRY (2017)
Prevention and management of glucocorticoid- induced side effects: A comprehensive review A review of glucocorticoid pharmacology and bone health
Avrom Caplan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid A nationwide osteoporosis survey
Shan-Fu Yu et al.
MEDICINE (2017)
Observations following discontinuation of long-term denosumab therapy
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2017)
The Incidence of Atypical Femoral Fractures in Patients with Rheumatic Disease: Yamagata Prefectural Committee of Atypical Femoral Fractures (YamaCAFe) Study
Yuya Takakubo et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2017)
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Lenore Buckley et al.
ARTHRITIS CARE & RESEARCH (2017)
UK clinical guideline for the prevention and treatment of osteoporosis
J. Compston et al.
ARCHIVES OF OSTEOPOROSIS (2017)
Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids
Luca Parente
BMC PHARMACOLOGY & TOXICOLOGY (2017)
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Elena Tsourdi et al.
BONE (2017)
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Ian R. Reid et al.
CALCIFIED TISSUE INTERNATIONAL (2017)
Multiple clinical vertebral fractures following denosumab discontinuation
A. D. Anastasilakis et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics
A. W. Popp et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials
M. A. Amiche et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice
Marilina Piemontese et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2016)
Notch Signaling and the Skeleton
Stefano Zanotti et al.
ENDOCRINE REVIEWS (2016)
Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database
Paul de Boissieu et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis
A. Balasubramanian et al.
OSTEOPOROSIS INTERNATIONAL (2016)
The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Rachel J. Black et al.
PLOS ONE (2016)
The incidence of and risk factors for developing atypical femoral fractures in Japan
Yoshitomo Saita et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2015)
Glucocorticoid-induced osteoporosis: who to treat with what agent?
Rene Rizzoli et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
Dae Hyun Kim et al.
PLOS ONE (2015)
Adverse Consequences of Glucocorticoid Medication: Psychological, Cognitive, and Behavioral Effects
Lewis L. Judd et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts
H. Johansson et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis
Karine Briot et al.
JOINT BONE SPINE (2014)
Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Yasuo Suzuki et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2014)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Risk of Serious Atrial Fibrillation and Stroke With Use of Bisphosphonates Evidence From a Meta-analysis
Abhishek Sharma et al.
CHEST (2013)
Targeting 11β-hydroxysteroid dehydrogenases: a novel approach to manipulating local glucocorticoid levels with implications for rheumatic disease
Rowan S. Hardy et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
The Osteocyte: An Endocrine Cell . . . and More
Sarah L. Dallas et al.
ENDOCRINE REVIEWS (2013)
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial
Claus-C Glueer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Renal Safety in Patients Treated With Bisphosphonates for Osteoporosis: A Review
Paul D. Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
The Disconnect Between Better Quality of Glucocorticoid-induced Osteoporosis Preventive Care and Better Outcomes: A Population-based Cohort Study
Sumit R. Majumdar et al.
JOURNAL OF RHEUMATOLOGY (2013)
Risk of Severe Upper Gastrointestinal Complications among Oral Bisphosphonate Users
Arianna Ghirardi et al.
PLOS ONE (2013)
Prevalence of oral glucocorticoid usage in the United States: A general population perspective
Robert A. Overman et al.
ARTHRITIS CARE & RESEARCH (2013)
Osteoporosis in the European Union: medical management, epidemiology and economic burden
E. Hernlund et al.
ARCHIVES OF OSTEOPOROSIS (2013)
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate
Philip N. Sambrook et al.
BONE (2012)
Management of Glucocorticoid-Induced Osteoporosis
R. Rizzoli et al.
CALCIFIED TISSUE INTERNATIONAL (2012)
Severe hypercalcemia due to teriparatide
Cumali Karatoprak et al.
INDIAN JOURNAL OF PHARMACOLOGY (2012)
Population-Based Trends in Osteoporosis Management after New Initiations of Long-Term Systemic Glucocorticoids (1998-2008)
S. R. Majumdar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Treatment failure in osteoporosis
A. Diez-Perez et al.
OSTEOPOROSIS INTERNATIONAL (2012)
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis
S. Lekamwasam et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Physiological Notch Signaling Maintains Bone Homeostasis via RBPjk and Hey Upstream of NFATc1
Xiaolin Tu et al.
PLOS GENETICS (2012)
Diretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Rosa Maria Rodrigues Pereira et al.
Revista Brasileira De Reumatologia (2012)
International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis
Samuel Vasikaran et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?
Juliet Compston
CLINICAL ENDOCRINOLOGY (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Glucocorticoid-induced osteoporosis in men
R. A. Adler et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2011)
Risk of hip fracture in Addison's disease: a population-based cohort study
S. Bjornsdottir et al.
JOURNAL OF INTERNAL MEDICINE (2011)
Glucocorticoid-Induced Bone Disease
Robert S. Weinstein
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Guidance for the adjustment of FRAX according to the dose of glucocorticoids
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years
Laurence Fardet et al.
RHEUMATOLOGY (2011)
Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies
Yoon K. Loke et al.
THORAX (2011)
Advances in Glucocorticoid-Induced Osteoporosis
Debby den Uyl et al.
CURRENT RHEUMATOLOGY REPORTS (2011)
Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice
Robert S. Weinstein et al.
AGING CELL (2010)
Resolution of Oral Bisphosphonate and Steroid-Related Osteonecrosis of the Jaw-A Serial Case Analysis
Chang-Ta Chiu et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2010)
Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis
Jean-Pierre Devogelaer et al.
JOURNAL OF RHEUMATOLOGY (2010)
Skeletal Diseases in Cushing's Syndrome: Osteoporosis versus Arthropathy
Gregory Kaltsas et al.
NEUROENDOCRINOLOGY (2010)
Effects of Teriparatide Versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial
Kenneth G. Saag et al.
ARTHRITIS AND RHEUMATISM (2009)
Age Dependence of Early Symptomatic Vertebral Fracture with High-Dose Glucocorticoid Treatment for Collagen Vascular Diseases
Ichiro Tatsuno et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial
David M. Reid et al.
LANCET (2009)
Minireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells
Lorenz C. Hofbauer et al.
MOLECULAR ENDOCRINOLOGY (2009)
Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis - A longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice
Wei Yao et al.
ARTHRITIS AND RHEUMATISM (2008)
Modulation of dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss
Feng-Sheng Wang et al.
ENDOCRINOLOGY (2008)
Relationship between extracellular matrix, contractile apparatus, muscle mass and strength in case of glucocorticoid myopathy
Eva-Maria Riso et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2008)
Osteoporosis in men
Peter R. Ebeling
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science
J. Compston et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Skeletal Effects of Systemic and Topical Corticosteroids
Peter Vestergaard
CURRENT DRUG SAFETY (2008)
A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients
F. Jadu et al.
ANNALS OF ONCOLOGY (2007)
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
E. Canalis et al.
OSTEOPOROSIS INTERNATIONAL (2007)
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2007)
The safety of zoledronic acid
Allan Lipton
EXPERT OPINION ON DRUG SAFETY (2007)
Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6
Sylvie Huybers et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
Fracture risk with intermittent high-dose oral glucocorticoid therapy
Frank de Vries et al.
ARTHRITIS AND RHEUMATISM (2007)
Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density
D. Jia et al.
ENDOCRINOLOGY (2006)
Glucocorticoids suppress bone formation via the osteoclast
Hyun-Ju Kim et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial bones
Charlotte Swanson et al.
ENDOCRINOLOGY (2006)
Mechanisms of disease - Bone quality - The material and structural basis of bone strength and fragility
Ego Seeman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Glucocorticoid-induced osteoporosis: an update
Gherardo Mazziotti et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2006)
High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130:: an additional mechanism for early increased bone resorption
Andrea Dovio et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Inhaled steroids do not decrease bone mineral density but increase risk of fractures:: Data from the GIUMO study group
M. Sosa et al.
JOURNAL OF CLINICAL DENSITOMETRY (2006)
Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice
NE Lane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis
T. P. van Staa
CALCIFIED TISSUE INTERNATIONAL (2006)
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club
JP Devogelaer et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Two Polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression
H Russcher et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Fracture risk associated with systemic and topical corticosteroids
P Vestergaard et al.
JOURNAL OF INTERNAL MEDICINE (2005)
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts
K Ohnaka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects
S Bonadonna et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Pharmacokinetics/pharmacodynamics of bisphosphonates - Use for optimisation of intermittent therapy for osteoporosis
SCLM Cremers et al.
CLINICAL PHARMACOKINETICS (2005)
Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k
Y Liu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
11β-hydroxysteroid dehydrogenases:: changing glucocorticoid action
JR Seckl
CURRENT OPINION IN PHARMACOLOGY (2004)
A meta-analysis of prior corticosteroid use and fracture risk
JA Kanis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-β by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts
A Takuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence?
B Cryer et al.
MAYO CLINIC PROCEEDINGS (2002)
The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence
MR Rubin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure
MS Cooper et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Cortisol regulates the expression of Notch in osteoblasts
RMR Pereira et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2002)
The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis
TP van Staa et al.
OSTEOPOROSIS INTERNATIONAL (2002)
Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts:: An autocrine switch from glucocorticoid inactivation to activation
MS Cooper et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Risedronate - A review of its pharmacological properties and clinical use in resorptive bone disease
CJ Dunn et al.
DRUGS (2001)
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
TP van Staa et al.
RHEUMATOLOGY (2000)
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy
S Wallach et al.
CALCIFIED TISSUE INTERNATIONAL (2000)
Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation
JR Ferraris et al.
PEDIATRIC NEPHROLOGY (2000)
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial
DM Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Use of oral corticosteroids in the United Kingdom
TP van Staa et al.
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS (2000)
Management of corticosteroid-induced osteoporosis
JD Adachi et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2000)
Share Paper
